Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this case report, a 7-year-old boy with alopecia totalis experienced significant hair regrowth after adding topical tofacitinib and mometasone to his treatment regimen, suggesting potential benefits of topical Janus kinase inhibitors for pediatric patients with this condition.

This study discovered that the gene Tfap2b identifies a melanocyte stem cell population in zebrafish, essential for regenerating melanocytes with multi-fate potential into adult pigment cells.

This study highlights that while there are no FDA- or ANVISA-approved treatments for children with alopecia areata, JAK inhibitors are emerging as a promising therapeutic option for this population.

This study found that the Arabidopsis cation chloride cotransporter CCC1 is critical for regulating pH in the trans-Golgi network/early endosome, impacting plant growth and stress response.

This study found that coadministration of tadalafil and finasteride improved lower urinary tract symptoms and erectile function in men with benign prostatic hyperplasia better than finasteride alone over 26 weeks.

In this case report, a female patient with Graham-Little-Piccardi-Lassueur Syndrome and hidradenitis suppurativa showed significant improvement in symptoms, including hair loss and lesions, after six months of treatment with tofacitinib, with no recurrence or adverse effects over a two-year follow-up.

This study reports that sacituzumab govitecan achieved a 33.3% overall response rate in patients with metastatic triple-negative breast cancer who had prior treatments, with a median response duration of 7.7 months.

In this study, researchers identified a specific T cell receptor associated with carbamazepine-induced severe cutaneous adverse reactions, demonstrating its potential for therapeutic development in patients with the HLA-B*15:02 genotype.

This study reported six pediatric cases of temporal triangular alopecia and highlighted the use of trichoscopy to distinguish it by detecting a distinctive carpet of vellus hair, helping to differentiate TTA from other hair loss conditions.

This case report details the successful use of oral tofacitinib for six months, which led to significant hair regrowth in an adult male Indian patient with extensive and refractory alopecia areata, highlighting tofacitinib's potential in managing resistant cases within this population.

This study reports a novel mutation in the TP63 gene associated with T and B cell lymphopenia in an EEC patient, suggesting that EEC diagnosis should include TREC assay and evaluation for immunodeficiency.

This literature review indicates that tofacitinib, both orally and topically, holds promise as a safe and effective treatment for various dermatological conditions in pediatric patients, though its use requires careful consideration of its benefits and risks.

This case study reported that a 24-year-old patient with severe, treatment-resistant alopecia areata experienced excellent clinical improvement after one month of treatment with tofacitinib, a JAK inhibitor.

This study found that transcutaneous electrical acustimulation aided wound healing in mice by enhancing expression of proteins related to signaling pathways, stress recovery, and mitochondrial function.

This report describes the diagnosis and treatment of traumatic anserine folliculosis in children, highlighting its distinct skin features and suggesting tretinoin cream as an effective remedy.

This clinical case report describes a patient with ulcerative colitis whose symptoms improved using the Janus kinase inhibitor, tofacitinib, allowing disease remission and hair regrowth.

This study found a specific T cell receptor that may be key in carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis, suggesting potential therapeutic targets.

This study evaluated the effectiveness and safety of ritlecitinib in patients aged 12 or older with alopecia totalis or universalis, finding higher hair regrowth response rates compared to placebo at 24 weeks, with continued improvement and acceptable safety through 48 weeks.

In this study, two patients with alopecia universalis continued using tofacitinib during active COVID-19 infection and showed no worsening of their illness, despite potential concerns about immunosuppression.

This report suggests a possible association between temporal triangular alopecia and sebaceous nevus, and identifies a pinkish background as a new trichoscopic finding for TTA.

This phase 1 study reported that after administering supratherapeutic doses of cortexolone 17α‐propionate, a topical antiandrogen intended for hair loss treatment, there was no effect on the QTc interval, indicating no measurable cardiac safety concerns in the concentration range tested.

In this pediatric retrospective study, tofacitinib (a Janus kinase inhibitor) improved the severity of alopecia and quality of life more effectively than traditional treatment methods, with significant reductions in alopecia severity score and dermatology life quality index over 16 weeks.

This case report identifies a 23-year-old man with congenital triangular alopecia, a non-scarring alopecia characterized by preserved follicles and vellus hair, for which unnecessary interventions should be avoided.

This source discusses the potential of topical JAK inhibitors, like tofacitinib, as effective treatments for autoimmune skin diseases, emphasizing their superior safety profile and minimal adverse effects compared to conventional systemic therapies.

This study introduces the Hair Cell Analysis Toolbox (HCAT), a machine-learning software that automates the analysis of cochlear hair cells, enabling unbiased and comprehensive imaging data interpretation.

This study found that LEF1/TCF3 is necessary but not sufficient for TOPGAL activation in hair follicle development, indicating complex regulation in the skin.

In this study, ritlecitinib, an oral JAK3/TEC inhibitor, was evaluated for safety in patients aged 12 and older with alopecia areata across four clinical trials up to 36 months, showing a safety profile with reported adverse events and lab abnormalities summarized per dosing groups.